✦ LIBER ✦

Sequential Versus Alternating Administration of Cisplatin/Etoposide and Topotecan as First-Line Treatment in Extensive-Stage Small-Cell Lung Cancer: Preliminary Results of a Phase III Trial of the Hellenic Oncology Research Group

✍ Scribed by Michail Ignatiadis; Dimitris Mavroudis; Marinos Veslemes; John Boukovinas; Kostas Syrigos; Maria Agelidou; Athina Agelidou; Aleka Gerogianni; Georgia Pavlakou; Evaggelos Tselepatiotis; John Nikolakopoulos; Vassilis Georgoulias

Book ID: 115076603
Publisher: CIG Media Group, LP.
Year: 2005
Tongue: English
Weight: 152 KB
Volume: 7
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2005.n.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel-cisplatin-etoposide (TEP) ver

Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial

✍ D. Mavroudis; E. Papadakis; M. Veslemes; M. Agelidou; M. Toubis; A. Agelidou; J. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Alternating chemotherapy with etoposide

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma : A Phase II trial of the North Central Cancer Treatment Group

✍ James R. Jett; Alan K. Hatfield; Shauna Hillman; Michael D. Bauman; James A. Mai 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views

## Abstract ## BACKGROUND The objective of this study was to test the response rate and toxicity of alternating chemotherapy in previously untreated patients with extensive‐stage small cell lung carcinoma (SCLC). ## METHODS Patients with histologically proven, extensive‐stage SCLC, with a perfor

Docetaxel and gemcitabine combination, a

Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

✍ Skarlos, Dimosthenis-Vasilios; Dimopoulos, Athanassios-Meletios; Kosmidis, Paras 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Common arm comparative outcomes analysis

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer : Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124

✍ Primo N. Lara Jr; Kari Chansky; Taro Shibata; Haruhiko Fukuda; Tomohide Tamura; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

Phase II trial of topotecan and paclitax

Phase II trial of topotecan and paclitaxel (TP) with G-CSF support alternating with etoposide and cisplatin (EC) in previously untreated extensive stage small cell lung cancer (ED-SCLC): A North Central Cancer Treatment Group study

✍ Jett, J.R; Hatfield, A; Bauman, M; Hillman, S; Soori, G; Veeder, M; Morton, R 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Randomised phase II study of amrubicin a

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

✍ Mary E.R. O’Brien; Krzystof Konopa; Paul Lorigan; Lionel Bosquee; Ernest Marshal 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 277 KB